Paolo Cortesi discusses the value of axi-cel as a second-line treatment in patients with R/R LBCL - VJHemOnc

Paolo Cortesi discusses the value of axi-cel as a second-line treatment in patients with R/R LBCL – VJHemOnc

VJHemOnc shared on X:

“Paolo Cortesi (The University of Milano–Bicocca) discusses the value of axi-cel as a second-line treatment in patients with R/R LBCL in an insightful interview from EBMT2024.

Click here to check it out.” .

Link to video.
Source: VJHemOnc/X

Axi-cel cancer EBMT2024 OncoDaily Oncology Paolo Cortesi The University of Milano-Bicocca VJHemOnc